Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lux receives US FDA complete response letter for uveitis drug

This article was originally published in Scrip

Executive Summary

Lux Biosciences has received a complete response letter from the US FDA for Luveniq (oral voclosporin, LX211; licensed from Isotechnika Pharma), its treatment candidate for non-infectious uveitis. It requested that an additional clinical trial is conducted in order for an approval to be considered. Lux said it would conduct an additional pivotal study of Luveniq, which it expects to begin before the end of the year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC009801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel